TABLE 2.
Baseline comparison of patient demographics and ulcer characteristics
| Baseline characteristics |
Author (reference) |
||||
|---|---|---|---|---|---|
| Hung et al (23) | Zargar et al (22) | Hsu et al (24) | Jensen et al (25) | Tsibouris et al (26) | |
| Cases, n (T/C) | 54/49/50* | 102/101 | 52/50 | 72/77 | 82/82 |
| Age, years, mean (SD) (T/C, n) | 63.7 (NA)/57.8 (NA)/62.5 (NA) | 55.3 (9.2)/52.4 (8.8) | 63.2 (18.2)/64.7 (13.8) | 59.6 (16.1)/55.6 (16.8) | 67.8 (13.1)/66.4 (13) |
| NSAID use, n (T/C) | 15/11/10 | 18/15 | 14/16 | 69/71 | 57/57 |
| HP-positive, n (T/C) | 33/30/26 | 62/58 | NA | 41/27 | 60/60 |
| History of ulcer bleeding, n (T/C) | NA | 21/18 | 14/9 | NA | NA |
| GU, n (T/C) | 19/14/20 | 18/16 | 25/25 | 34/31 | 44/44 |
| DU, n (T/C) | NA | 84/85 | 27/25 | 37/46 | 38/38 |
| Ulcer size, cm (SD) (T/C) | 1.2 (NA)/1.1 (NA)/1.0 (NA) | 1.2 (0.8)/1.3 (0.8) | 1.2 (0.8)/1.2 (0.6) | 1.1 (0.5)/1.2 (0.5) | 1.3 (0.6)/1.2 (0.6) |
| Inpatient bleeding, n (T/C) | NA | 12/14 | NA | NA | 5/5 |
| Hemoglobin on admission, (g/L) (SD) (T/C) | 94 (NA)/101 (NA)/98 (NA) | 94 (1.8)/91 (21) | 103 (30)/100 (28) | NA | NA |
| Shock on admission, n (T/C) | 1/1/1 | 28/24 | 3/3 | NA | 36/36 |
| Comorbid diseases, n (T/C) | NA | 25/22 | NA | NA | 46/46 |
| Endoscopic appearance, n (T/C) | |||||
| Spurting bleeding | 6/5/4 | 12/14 | 4/2 | 35/37 | 16/16 |
| Oozing bleeding | 28/24/29 | 25/31 | 18/17 | 33/36 | 36/36 |
| Nonbleeding visible vessel | 5/8/3 | 65/56 | 18/21 | 4/4 | 30/30 |
| Adherent clot | 33/31/28 | –/– | 12/12 | –/– | –/– |
*
Continuous infusion n=54, bolus infusion n=49, no treatment n=50. C Control subjects; DU Duodenal ulcer; GU Gastric ulcer; HP Helicobacter pylori; NA Not applicable; NSAID Nonsteroidal anti-inflammatory drug; T Treated subjects